Oppenheimer analyst Leland Gershell raised the firm’s price target on Argenx (ARGX) to $778 from $708 and keeps an Outperform rating on the shares. The firm notes Global Vyvgart sales of $949Mmarkedly outpaced its/consensus estimates of $872M/$868M, with newly available pre-filled syringe and CIDP launch momentum being key drivers.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $788 from $680 at Baird
- Argenx Se’s Strong Market Position and Impressive Financial Performance Drive Buy Rating
- Argenx price target raised to $774 from $720 at H.C. Wainwright
- Argenx Reports Strong Growth and Strategic Advances
- Argenx Earnings Call: Strong Growth and Innovation